219 related articles for article (PubMed ID: 34846682)
1. Speed of response to dopaminergic agents in prolactinomas.
Hage C; Salvatori R
Endocrine; 2022 Mar; 75(3):883-888. PubMed ID: 34846682
[TBL] [Abstract][Full Text] [Related]
2. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
3. Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study.
Portari LHC; Correa-Silva SR; Abucham J
Neuroendocrinology; 2022; 112(1):68-73. PubMed ID: 33477154
[TBL] [Abstract][Full Text] [Related]
4. Pituitary production of prolactin and prolactin-suppressing drugs.
Tansey MJ; Schlechte JA
Lupus; 2001; 10(10):660-4. PubMed ID: 11721691
[TBL] [Abstract][Full Text] [Related]
5. Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.
Kontbay T; Şıklar Z; Özsu E; Uyanık R; Bilici E; Ceran A; Berberoğlu M
Turk J Pediatr; 2022; 64(5):892-899. PubMed ID: 36305439
[TBL] [Abstract][Full Text] [Related]
6. Giant prolactinomas, a detailed analysis of 196 adult cases.
Lisa B; Arno V; Christophe B; Heyning Paul V; Carlien H
Pituitary; 2023 Oct; 26(5):529-537. PubMed ID: 37544978
[TBL] [Abstract][Full Text] [Related]
7. [Current diagnosis and treatment of hyperprolactinemia].
Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M
Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213
[TBL] [Abstract][Full Text] [Related]
8. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.
Schwetz V; Librizzi R; Trummer C; Theiler G; Stiegler C; Pieber TR; Obermayer-Pietsch B; Pilz S
Metab Brain Dis; 2017 Feb; 32(1):155-161. PubMed ID: 27525431
[TBL] [Abstract][Full Text] [Related]
10. Drug treatment of hyperprolactinemia.
Chanson P; Borson-Chazot F; Chabre O; Estour B
Ann Endocrinol (Paris); 2007 Jun; 68(2-3):113-7. PubMed ID: 17532288
[TBL] [Abstract][Full Text] [Related]
11. Prolactin, prolactin disorders, and dopamine agonists during pregnancy.
Levin G; Rottenstreich A
Hormones (Athens); 2019 Jun; 18(2):137-139. PubMed ID: 30341577
[TBL] [Abstract][Full Text] [Related]
12. Prolactinomas.
Wildemberg LE; Fialho C; Gadelha MR
Presse Med; 2021 Dec; 50(4):104080. PubMed ID: 34687915
[TBL] [Abstract][Full Text] [Related]
13. The Prolactin per Unit Tumor Volume Ratio Accurately Distinguishes Prolactinomas From Secondary Hyperprolactinemia due to Stalk Effect.
Faje A; Jones P; Swearingen B; Tritos NA
Endocr Pract; 2022 Jun; 28(6):572-577. PubMed ID: 35339688
[TBL] [Abstract][Full Text] [Related]
14. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
15. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new.
Chanson P; Maiter D
Best Pract Res Clin Endocrinol Metab; 2019 Apr; 33(2):101290. PubMed ID: 31326373
[TBL] [Abstract][Full Text] [Related]
16. Mucocele-like formation leading to neurological symptoms in prolactin-secreting pituitary adenomas under dopamine agonist therapy.
Abe T; Lüdecke DK
Surg Neurol; 1999 Sep; 52(3):274-9. PubMed ID: 10511086
[TBL] [Abstract][Full Text] [Related]
17. Hyperprolactinemia after menopause: Diagnosis and management.
Auriemma RS; Pirchio R; Pivonello R; Colao A
Maturitas; 2021 Sep; 151():36-40. PubMed ID: 34446277
[TBL] [Abstract][Full Text] [Related]
18. Hyperprolactinaemia.
Prabhakar VK; Davis JR
Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):341-53. PubMed ID: 17889620
[TBL] [Abstract][Full Text] [Related]
19. Women with prolactinomas presented at the postmenopausal period.
Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
[TBL] [Abstract][Full Text] [Related]
20. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
